1,4-andro (1,4-androstadienedione) and 1,4-androdiol (1,4-androstadienediol)
are both prohormones to the steroid boldenone. 1,4-andro is well known as
the most orally active prohormone, with a recovery rate as high as 50%. This
is because its chemical structure renders it resistant to first pass metabolism
in the liver. However, unlike many other steroidal compounds, the chance
of liver toxicity from oral administration is very low.
Boldenone (1,4-androstadiene-3-one,17b-ol) is an injectable veterinary steroid
most commonly found as Equipoise (used for horses). It is structurally related
to testosterone and methyl-testosterone, and a small amount (10-20%) may
metabolize into testosterone. It is very popular among bodybuilders and other
athletes because of its unique characteristics. It is highly anabolic, while
having only low-moderate androgenic effects and low estrogenic effects. This
is because it is a poor substrate for 5-alpha reductase and has low aromatization
to estrogen. Boldenone is commonly stacked with other steroids, and it has
the reputation of leading to smaller, more consistent, and easier to keep
gains as opposed to rapid muscle gains which are difficult to maintain off
cycle. Other reputed effects of boldenone include increased pumps and muscle
hardness and increased appetite.
A low dose of 1,4-andro falls in the range of 300-600 mg daily, with a medium
dose being in the range of 600-1000 mg. It is good for both cutting or bulking,
and can be stacked with most compounds depending on the situation. Cycle
length is usually on the longer side, around 4-12 weeks, because it usually
takes around 3 weeks for most users to notice an effect. This is because
boldenone has a long half-life, so the effects build up over time. The difference
between the dione and diol versions is that the dione version converts to
estrogen (at about half the rate that testosterone does), while the diol
version does not.
If you have any questions or comments regarding this article, please email
dvdtlsn@bulknutrition.com.
No part of this article may be reproduced in any form without the permission of David Tolson or Mike McCandless.
